Table 1.

Characteristics of the patients with CCPD and gout treated by biologics in western France

	CCPD	Gout	p value
Number	15 (32.6)	31 (67.4)
Sex female/total	10 (66.7)	6 (19.4)	0.005
Age	75.0 (64.0–84.5)	67.0 (60.0–74.0)	0.017
Weight	84.0 (73.0–87.0)	85.0 (76.15-93.0)	0.139
Height	157.0 (154.0–171.5)	173.5 (164.2–176.5)	0.041
Cellularity of synovial fluid	700 (300–14,000)	13100 (5750–22,500)	0.150
Crystals in synovial fluid	5/10 (50.0)	18/21 (85.7)	0.110
Uricaemia before treatment, μmol/L	310.0 (246.5–369.5)	527.0 (432.0–623.0)	< 0.001
Clearance, mL/min	81.15 (78.05–88.0)	54.0 (34.25–69.25)	< 0.001
CRP before treatment, mg/L	24.50 (4.10–83.80)	56.0 (4.15–112.5)	0.363
Positive RF (n = 27)	4/12 (33.3)	1/15 (6.6)	0.021
Positive ACPA (n = 27)	3/12 (25.0)	1/15 (6.6)	0.046
Positive ANA > 1/80 (n = 28)	3/12 (25.0)	10/20 (50.0)	0.270
Arthritis before treatment	3.50 (2.0–4.75)	4.0 (2.0–5.0)	0.755
Arthritis after treatment	2.0 (1.0–2.75)	0.0 (0.0–0.75)	0.073
Tophus before treatment	0 (0.0)	21 (67.7)	< 0.001
1st MTP arthritis (≥ 1) before treatment (n = 45)	1/14 (7.1)	17/31 (45.9)	0.011
1st MCP arthritis (≥ 1) before treatment (n = 44)	4/14 (28.6)	4/30 (13.3)	0.415
Hand arthritis (≥ 1) before treatment (n = 46)	10/15 (66.7)	14/31 (45.2)	0.327
Foot arthritis (≥ 1) before treatment (n = 46)	2/15 (13.3)	16/31 (51.7)	0.042
Knee arthritis (≥ 1) before treatment (n = 43)	6/14 (42.9)	18/29 (62.1)	0.238
Other arthritis before treatment
0	5 (33.3)	22 (71.0)
1	6 (40.0)	4 (12.9)
2–3	3 (20.0)	3 (9.7)
≥ 4	1 (6.7)	2 (6.5)

Data are presented as n (%) or median (Q1–Q3)

CCPD calcium pyrophosphate crystal deposition, CRP C-reactive protein, RF rheumatoid factor, ACPA anti-citrullinated protein antibodies, ANA antinuclear antibody, MTP metatarsophalangeal, MCP metacarpophalangeal, Q1–Q3 quartile range 1–quartile range 3